Trevi Therapeutics (TRVI) Interest Expenses (2018 - 2022)
Trevi Therapeutics (TRVI) posted quarterly Interest Expenses of $210000.0 for Q1 2026, up 29.63% year-over-year from $162000.0 in Q1 2025, and up 180.77% quarter-over-quarter from -$260000.0 in Q4 2025.
Powered by 
Analysis
Trevi Therapeutics (TRVI) Interest Expenses (2018 - 2022) Analysis & Trends
Trevi Therapeutics' Interest Expenses history runs 9 years deep, the most recent figure standing at $210000.0 for Q1 2026.
- In Q1 2026, Interest Expenses rose 29.63% year-over-year to $210000.0; the TTM figure through Mar 2026 stood at $210000.0 (up 29.63% YoY), while the FY2025 annual figure was $82.7 million, up 608.91% from the prior year.
- Interest Expenses for Q1 2026 stood at $210000.0, up from -$260000.0 in the prior quarter.
- The five-year high for Interest Expenses was $1.4 million in Q1 2024, with the low at -$260000.0 in Q4 2025.
- The 5-year median for Interest Expenses is $231000.0 (2023), against an average of $402764.7.
- The sharpest annual moves came in 2024 and 2025: Interest Expenses surged 779.08% in 2024, then slumped 26100.0% in 2025.
- Trevi Therapeutics' Interest Expenses stood at $499000.0 in 2022, then tumbled by 111.22% to -$56000.0 in 2023, then surged by 101.79% to $1000.0 in 2024, then plunged by 26100.0% to -$260000.0 in 2025, then surged by 180.77% to $210000.0 in 2026.
- Business Quant data shows TRVI's Interest Expenses at $210000.0 in Q1 2026, -$260000.0 in Q4 2025, and $937000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 11.00 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | -1.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 23.78 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 39.74 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 82.05 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 93.62 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 20.27 Mn |
| 10 | Trevi Therapeutics | 2.71 Bn | 2.71 Bn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2022 | 274,000.00 |
| Sep 30, 2022 | 292,000.00 |
| Jun 30, 2022 | 295,000.00 |
| Mar 31, 2022 | 302,000.00 |
| Dec 31, 2021 | 309,000.00 |
| Sep 30, 2021 | 303,000.00 |
| Jun 30, 2021 | 375,000.00 |
| Mar 31, 2021 | 294,000.00 |
| Dec 31, 2020 | 308,000.00 |
| Sep 30, 2020 | 148,000.00 |
| Jun 30, 2018 | 51,000.00 |
| Mar 31, 2018 | 123,000.00 |